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PREPARATION OF BIODEGRADABLE 
MICROSPHERES USEFUL AS CARRIERS FOR 
MACROMOLECULES 
BACKGROUND OF THE INVENTION 
(1) Field of the Invention 
The present invention relates generally to the ?eld of 
biodegradable polymers for the controlled release of 
biologically active agents therefrom. More particularly, 
the present invention relates to a process for preparing 
biodegradable polymers in the form of spherical parti 
cles of controlled size. The process is designed to allow 
the biodegradable polymer particles to contain incorpo 
rated biologically active agents and to allow controlled 
release of these agents while allowing targeted delivery 
via injection or inhalation. 
(2) Background of the Prior Art 
The use of proteins and peptides as therapeutic agents 
has been recognized and their position within the phar 
maceutical arrnamentarium is growing due to their in 
creasing availability. This availability is primarily due 
to recent advances in genetic engineering and biotech 
nology. Unfortunately, the use of proteinaceous drugs 
by conventional routes of administration is generally 
hampered by a variety of delivery problems. Nonpar 
enteral routes of administration, i.e., oral and percutane 
ous, are inef?cient primarily due to poor absorption of 
proteinaceous drugs into the bloodstream and degrada 
tion of such drugs in the gastrointestinal tract. Rapid 
proteolytic inactivation of the proteinaceous drug also 
occurs when the drug is administered parenterally thus 
decreasing its bioavailability. In addition, when admin 
istered by the parenteral route, the host’s immune sys 
tem is activated thereby potentially setting off a series of 
undesirable immune reactions. 
In view of the foregoing, considerable effort has been 
devoted to developing alternative systems for paren 
teral delivery of peptides and proteins to obviate the 
problems associated with prior art administration tech 
niques. For instance, implantable devices have been cast 
or molded from poly-(hydroxyethyl)methacrylate, pol 
yvinyl alcohol, ethylene-vinylacetate copolymer 
(EVA) and silicone elastomer. Macromolecular drugs 
have been embedded in those devices. A typical method 
of preparation involves suspending a powder of a mac 
romolecular drug such as a solid protein or peptide in a 
solution containing the polymer. The entire composi 
tion is then cast or molded into the desired size and 
shape either by evaporating the solvent or by vulcaniza 
tion. A sustained release of macromolecules from these 
devices has been demonstrated. The simplicity of the 
foregoing prior art method is its primary advantage. 
However, one disadvantage of hydrophobic poly 
mers such as those prepared from EVA and silicon, is 
that those polymers are not permeable to hydrophilic 
macromolecules, thus, only that portion of the drug 
which communicates with the surface of the implant, 
either directly orvia contact with other drug particles, 
can be released. Thus, the drug present nearer the inte 
rior of the implant and completely surrounded by the 
polymer matrix is unable to ever be released and never 
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exerts its therapeutic effect. Addition of polar additives _ 
increases penetration of water in these hydrophobic 
materials and helps to dissolve the protein, but they are 
not quite inert to the protein, as are the polar organic 
solvents used for casting from PHEMA and PVA. An 
other disadvantage associated with these types of de 
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vices is the need for surgical insertion and eventually 
surgical removal of the implant. This is necessary since 
the devices are composed of materials which are nonde 
gradable. 
Microspheres containing proteins have been prepared 
from polyacrylamide, acryloylated dextran and 
acryloylated starch. Polyacrylamide beads can meet 
different purposes in vitro, but their nondegradability 
prevents their use in humans. Reported data on polysac 
charide particles show that an ef?cient crosslinking has 
been achieved only at a high degree of derivatization 
(D.D. about 0.1 to 0.3). A high DD. is disadvantageous 
as it decreases the biocompatibility of the polymer. A 
high D.D. also leads preferentially to the intramolecular 
reaction of polymerizable groups instead of the inter- ’ 
molecular reaction between different polymer chains, 
which results in a heterogenous microporous structure. 
The use of the crosslinking agent bisacrylamide is not 
considered desirable, since it generally results in the 
formation of crosslinked hydrocarbon gels, which nei 
ther dissolve nor degrade even after degradation of the 
polysaccharide component. 
The recent advances in the incorporation of drugs 
into microparticulate carriers has attracted a great deal 
of attention because it combines features of matrix-con 
trolled release with those of injectable forms. In addi 
tion to controlled release, these microspherical carriers 
offer “?rst stage” physical targeting, that is, physical 
localization of the drug carrier in the proximity of the 
target tissue and cells. Localized administration of the 
therapeutic agent allows for not only more ef?cient 
drug therapy but also minimizes the opportunity for 
adverse systemic effects. 
In preparing microspheres in the size range of 1 pm 
to 20 um, homogenous systems are more suitable than 
heterogenous systems for casting implants. In the ho 
mogenous system, proteins are co-dissolved in the same 
solvent as the material of the matrix. Furthermore, in 
order to preserve the biological activity of the macro 
molecules, aqueous systems are generally preferred. In 
this regard, biodegradable hydrophilic polymers can be 
chosen as matrix material provided that they can be 
solidi?ed or crosslinked by a mechanism which does 
not involve a chemical modi?cation and/or denatura 
tion of the incorporated macromolecule such as a pro 
teinaceous agent. 
It is known that crosslinked hydrophilic gels can be 
obtained utilizing techniques of free-radical polymeriza 
tion. To some extent, the problems identi?ed above are 
similar to those found in the preparation of graft biode 
gradable polymers, that is, polymers containing vinylic 
groups with the encapsulation of biologically active 
materials therein. 
Examples of prior art patents include US. Pat. Nos. 
4,131,576, 3,687,878, 3,630,955 and 3,950,282. These 
patents disclose methods for the preparation of graft 
copolymers of polysaccharides and vinylic monomers. 
These patents were directed to improving the physical 
properties of the polysaccharides within each composi 
tion. Process conditions used to achieve these improve 
ments included the use of elevated temperatures, highly 
reactive monomers or organic solvents. However, each 
of the foregoing parameters are harmful to biologically 
active macromolecules and thus are unsuitable in the 
practice of the present invention. 
The prior art also discloses procedures for encapsula 
tion of a core material in a polymer capsule. US. Pat. 
4,741,872 
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No. 4,382,813 discloses the the production of a capsule 
wall by the gelation of polysaccharide gums, such as 
alkali-metal alginates, with bivalent metal cations. US. 
Pat. No. 4,344,857 discloses the gelation of xanthates of 
polyhydroxy polymers by the addition of strong acids 
and coupling agents. US. Pat. No. 3,567,650 achieves a 
similar result by lessening the solubility of certain poly 
meric materials using increasing temperature. 
Other mechanisms are based on the principle of com 
plex coacervation using at least two colloids of opposite 
electrical charge and oxidation products of polysaccha 
rides as crosslinking agents as disclosed in U.S. Pat. No. 
4,016,098. Yet another procedure employs interfacial 
crosslinking of the wall-forming polymer by reactive 
bifunctional crosslinking agents dissolved in oil droplets 
which are encapsulated as taught in U.S. Pat. No. 
4,308,165. Other examples of the prior art which offer 
similar teachings include US. Pat. Nos. 4,078,051, 
4,080,439, 4,025,455 and 4,273,672. Materials which are 
encapsulated according to the prior art are mostly 
water insoluble solids or oil droplets and compounds 
dissolved therein, e.g., dyes, pigments or biologically 
active low-molecular-weight compounds like herbi 
cides. 
US. Pat. No. 4,352,883 teaches a method for encap 
sulation of core materials such as living tissues or indi 
vidual cells in a semipermeable membrane. The mem 
brane is permeable for small molecules but not permea 
ble to large molecules. This patent also utilizes the gela 
tion of certain waterssoluble gums by the action of mul 
tivalent cations. 
US. Pat. No. 4,038,140 discloses the procedure for 
binding of biologically active proteins onto an insoluble 
carrier by reacting the proteins in an aqueous phase 
with a carrier comprising an activated polysaccharide 
having a hydrophilic graft copolymer incorporated 
therein. That patent is directed to the preparation of 
insoluble carriers containing covalently bound proteins 
with application in biochemical reactors. 
Yet another example of the prior art, US. Pat. No. 
4,094,833, teaches a procedure for preparation of 
copolymerizates of vinylic group containing dextran 
and divinyl compounds, optionally also monovinyl 
compounds, in the form of three-dimensional gel net 
works. The resulting crosslinked dextran-vinylic gels 
can be used for separation purposes. 
In spite of the numerous teachings of the prior art, the 
prior art does not offer a method for obtaining encapsu 
lated or entrapped biologically active macromolecules 
such as proteinaceous agents in spherical microparticles 
of controlled size ranges. Nor does the prior art suggest 
a procedure for allowing microspheres to have the 
potential to control the rate by which the biologically 
active macromolecule is released or for modulating the 
rate by which the matrix is degraded in vivo. 
SUMMARY OF THE INVENTION 
It is, therefore, the object of this invention to provide 
a process for the incorporation of sensitive biologically 
active macromolecules, preferably peptides and prote 
ins, into a biodegradable and biocompatible matrix 
under conditions sufficiently mild to retain the biologi 
cal activity of the incorporated macromolecular agents. 
It is another object of this invention to provide for a 
matrix, containing pharmacologically active macromol 
ecules, in the form of spherical particles of controlled 
size, preferably having a diameter in the range of about 
0.5 pm to about 500 pm. 
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It is also an object of this invention to produce micro 
spherical carriers from which macromolecular agents 
are released under in-vivo conditions at a predictable 
rate. 
It is yet another object of this invention to produce 
microspherical carriers of biologically active macro 
molecules which possess a potential for controlling the 
rate of biodegradation of the matrix so that the release 
of the macromolecular agents can be regulated by the 
biodegradation of the matrix. 
A further object of the present invention is to pro 
duce microspherical carriers of biologically active mac 
' romolecules which possess a potential for controlling 
the rate of biodegradation of the matrix by adjusting the 
matrix properties thereby controlling both release of the 
macromolecular agent and existence of the matrix in the 
tissue as well as assuring the biodegradation of the ma 
trix into nontoxic soluble products which are metabo 
lized and/0r excreted. 
A still further object of the present invention is to 
provide a microspherical drug delivery system which 
allows targeting of drugs or other agents to speci?c host 
tissues or cells via injection or inhalation providing high 
localized concentrations, sustained activity, systemic 
administration and treatment, thereby minimizing unde 
sirable systemic effects of toxic drugs administered di 
rectly into the circulation. 
These and similar objects, advantages and features 
are accomplished according to themethods and compo 
sitions of the following description of the present inven 
tion. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 depicts an overall scheme for preparation of 
the biodegradable microspheres of the present inven 
tion. 
FIG. 2 represents a more detailed view of the micro 
sphere prepared by the process depicted in FIG; 1. 
FIG. 3 depicts the cumulative release of alpha-l 
proteinase inhibitor from hydroxyethyl starchpolya 
crylamide microspheres in pg of protein per mg of 
microspheres. 
BRIEF DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The present invention provides a process for the 
incorporation of sensitive biologically active macro 
molecules into a biodegradable matrix. The biodegrad 
able matrix is prepared by the copolymerization of a 
vinyl derivative of biodegradable hydrophilic polymer 
containing at least two vinyl groups per polymer chain 
with a monovinyl water-soluble monomer. The biode 
gradable matrix is a three-dimensional gel network in 
which biologically active macromolecules are physi 
cally entrapped. The biodegradable matrix is particu 
larly well-suited for the parenteral route of administra 
tion. 
According to the present invention, the biodegrad 
able hydrophilic polymer component of the matrix can 
be selected from a variety of sources including polysac 
charides, proteinaceous polymers, soluble derivatives of 
polysaccharides, soluble derivatives of proteinaceous 
polymers, polypeptides, polyesters, polyorthoesters, 
and the like. 
The polysaccharides may be poly-1,4-glucans, e.g., 
starch glycogen, amylose and amylopectin, and the like. 
Preferably, the biodegradable hydrophilic polymer is a 
water-soluble derivative of a poly-1,4-glucan, including 
4,741,872 5 
hydrolyzed amylopectin, hydroxyalkyl derivatives of 
hydrolyzed amylopectin such as hydroxyethyl starch 
(HES), hydroxyethyl amylose, dialdehyde starch, and 
the like. 
Proteinaceous polymers and their soluble derivatives 
include gelation biodegradable synthetic polypeptides, 
elastin, alkylated collagen, alkylated elastin, and the 
like. ' 
Biodegradable synthetic polypeptides include poly 
(N-hydroxyalkyD-L-asparagine, poly-(N-hydroxy 
aIkyD-L-glutamine, copolymers of N-hydroxyalkyl-L 
asparagine and N-hydroxyalkyl-L-glutamine with other 
amino acids. Suggested amino acids include L-alanine, 
L-lysine, L-phcnylalanine, L-leucine, L-valine, L-tyro 
sine, and the like. 
De?nitions or further description of any of the fore 
going terminology are well known in the art and may be 
found by referring to any standard biochemistry refer 
ence text such as “Biochemistry” by Albert L. Lehn 
inger, Worth Publishers, ‘Inc. and “Biochemistry” by 
Lubert Stryer, W. H. Freeman and Company, both of 
which are hereby incorporated by reference. 
The aforementioned biodegradable hydrophilic poly 
mers are particularly suited for the methods and compo 
sitions of the present invention by reason of their char 
acteristically low human toxicity and virtually com 
plete biodegradability. of course, it will be understood 
that the particular polymer utilized is not critical and a 
variety of biodegradable hydrophilic polymers may be 
utilized as a consequence of the novel processing meth 
ods of the invention. 
The three dimensional network or gel matrix accord 
ing to the present invention is obtained by the free-radi 
cal polymerization of the biodegradable hydrophilic 
polymer containing at least two vinyl or substituted 
vinyl groups with an additional monovinylic monomer. 
The vinyl derivatives of the biodegradable hydro 
philic polymer include derivatives containing groups of 
the formula (I): 
CH2=CRt—(CH2)n—X (I) 
wherein R1 is a hydrogen atom or methyl group; n is 0, 
l or 2; and X is a radical having the formula 
wherein R2 represents the above-mentioned biodegrad 
able polymer which contains at least two vinyl or sub 
stituted vinyl groups per average polymer chain. Thus, 
. X represents an ether, secondary amine, ester or amide 
bridge between the group of formula (I) and the biode 
gradable hydrophilic polymer. Therefore, typical exam 
ples of vinyl substituents include vinyl, allyl, acryloyl, 
methacryloyl, acrylamido and methacrylamido groups. 
The vinyl derivatives of the biodegradable hydro 
philic polymer can be prepared in a variety of ways well 
known in the prior art. One suggested approach is the 
preparation of vinyl and allyl ethers by the reaction of 
vinyl alkylhalides, allylhalides, vinylglycidyl ethers or 
allylglycidyl ethers with alkaline solutions of the se 
lected biodegradable hydrophilic polymer containing 
either hydroxyl or amino groups. In a like manner, 
derivatives containing either ester or amide linkages can 
be prepared by reacting acryloyl chlorides, methacryl 
oyl chlorides, acryloyl glycidyl esters or methacryloyl 
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glycidyl esters with hydroxyl or amino groups of the 
biodegradable hydrophilic polymer. 
The degree of derivatization (DD) of the biodegrad 
able hydrophilic polymer by the vinyl groups is such, 
that they are at least two vinyl groups per average 
polymer chain, preferably, at least three vinyl groups 
per average polymer chain. The upper limit of DD is 
given by the desired density of crosslinking as discussed 
below. It should also be noted that the minimum DD, 
when expressed in moles of vinyl groups per mole of 
monomer units of biodegradable hydrophilic polymer 
also depends on the molecular weight of the biodegrad 
able hydrophilic polymer. 
The monovinyl monomer has two functions. First, it 
is intended to facilitate the propagation reaction of the 
growing radical by lessening steric hindrance during 
the polymerization of the macromolecular vinyl deriva 
tives. This obviates the necessity of a high degree of 
derivatization of the starting biodegradable hydrophilic 
polymer. And second, it is intended to introduce into 
the gel structure or matrix a nondegradable component 
which can participate in the regulation of the degrada 
tion rate of the matrix. 
The ratio of the monofunctional monomer propaga 
tor to derivatized biodegradable hydrophilic polymer is 
chosen such, that during the polymerization, short lin 
ear chains of hydrocarbon polymers are produced 
which are in fact crosslinked by degradable hydrophilic 
polymer chains. This assures that substantially the en 
tire matrix of microspheres can be degraded in vivo to 
low molecular weight soluble products. 
The ratio between the biodegradable hydrophilic 
polymer component to the vinyl monomer component 
may be in the range of about 1:5 up to about 40:1 based 
on a weight basis. Preferably, the ratio is in the range of 
about 2:1 to about 20:1. 
The monovinyl monomer is designed to facilitate the 
propagation reaction of the growing radical during 
polymerization thereby obviating the necessity of high 
derivatization of starting polysaccharide with polymer 
izable groups. The monovinyl monomer also introduces 
in the polymer matrix other functional groups, e.g., 
negatively or positively charged, which can participate 
in the control of drug release. Typical functional groups 
which may participate in the control of drug release 
include carboxyl, amino, dialkylamino, dihydroxyalk 
ylamino, and the like. The presence of these positive or 
negative charges provide ion-exchange properties to 
the matrix. 
The monovinyl monomer may be selected from the 
group of hydrophilic esters and/or amides of acrylic or 
methacrylic acids, water-soluble vinyl derivatives, 
acrylic acid, methacrylic acid, and the like. Typical 
examples of hydrophilic esters and/or amides of acrylic 
or methacrylic acids include acrylamide, methacrylam 
ide, 2-hydroxyethyl methacrylate, Z-hydroxypropyl 
methacrylamide, N-methylacryloyl-tris-hydroxyme 
thylaminomethane, N-acryloyl-N'-dimethylamino 
propylamine, 3-N,N-dimethylaminopropylmethacryla 
mide, N-alkylmethacrylamide glyceryl monomethacry 
late, and the like. Suitable water-soluble vinyl deriva 
tives include N-vinylpyrrolidone, N-vinylimidazole, 
p-vinylbenzoic acid, vinylpyridine, and the like. 
Suitable biologically active macromolecules intended 
to be used in the practice of the present invention in 
clude hormones, proteins, peptides, vaccines, enzymes, 
enzyme inhibitors and other biologically active macro 
molecules. A suggested inhibitor is alpha-l-antitrypsin 
4,741, 
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(ATT), an a-proteinase inhibitor. Additional examples 
include amino acid metabolizing enzymes in the treat 
ment of neoplasia, ?brinolytic enzymes, interferon, 
growth hormone, antigens for desensitization, immuno 
globulins and Fab-fragments of immunoglobulins. The 5 
present invention is not intended to be limited to any of 
the foregoing and other types of biologically active 
macromolecules are equally suitable in the practice of 
the present invention. 
The biologically active macromolecules remain free 
within the polymer matrix, that is, there are no chemical 
bonds between the macromolecule or some other group 
within the microsphere. Thus, the macromolecule does 
not require the breakage of a chemical bond to be re 
leased. Release occurs through diffusion out of the mi 
crosphere or biodegradable erosion of the polymer. 
The polymerization reaction according to the present 
invention is conducted under suitable conditions for 
free radical polymerization. The reaction is always con 
ducted in aqueous solution. Suitable free radical initia 
tors are redox type initiators. The polymerization reac 
tion is preferably conducted using free radical initiators 
to produce free radicals under mild conditions such as a 
temperature of approximately 0° C. However, the tem 
perature of the polymerization reaction may range from 
about 0° C. to about 50° C. The preferred temperature 
at which to conduct the polymerization reaction ranges 
from about 0° C. to about 30° C. 
It is a particularly advantageous feature of the present 
manufacturing procedure that, starting from the disso 
lution of the macromolecule of interest until dispensing 
the ?nal microspheres in vials, the entire process can be 
carried out at temperatures near 0° C. in order to mini 
mize the denaturation effect on the macromolecule. 
Typical redox type initiators include ammonium persul 
fate, hydrogen peroxide, benzoyl peroxide, and the like. 
It is also advantageous to use a free radical initiator 
along with a compound which forms with the initiator 
a redox system and accelerates the formation of radi 
cals. Examples of the second compound of the initiator 
system include N,N,N'N’-tetramethylethylenediamine, 
ascorbic acid, N,N=dimethylamino-p-toluidine, S-dime 
thylaminopropionitrile, sodium metabisul?te, and the 
like. 
During the polymerization reaction, linear chains of 45 
vinylic polymer are formed which are crosslinked with 
the biodegradable hydrophilic polymer. It is thus im 
portant that a monovinyl monomer is used during the 
polymerization reaction to ensure that only linear 
chains of nondegradable hydrocarbon polymers are 
formed. Thus, the use of the monovinyl monomer en 
sures that the degradation of the biodegradable compo 
nent which is responsible for the crosslinking will allow 
for the formation of totally soluble degradation prod 
ucts. The monovinyl monomer of the present invention, 
since it is only a monomer, will have a low molecular 
weight compared to the biodegradable polymer. It has 
been speculated that if the molecular weight of the 
monomer exceeds 400, then steric hindrance is possible. 
Thus, it is recommended for purposes of the present 
invention that the monovinyl monomer have a molecu~ 
lar weight of less than 400. 
The drug delivery system in accordance with the 
present invention is ideally suited for administration by 
parenteral or inhalation routes. It will be appreciated by 
those skilled in the art that the porous microspheres of 
the present invention containing incorporated drugs for 
release to target cells or tissues, therefore, may be ad 
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ministered alone or in admixture with appropriate phar 
maceutical diluents, carriers, excipients or adjuvants 
suitably selected with respect to the intended route of 
administration and conventional pharmaceutical prac 
tices. These inert pharmaceutically acceptable adju 
vants are well known in the art. For example, for paren 
teral injection, dosage unit forms may be utilized to 
accomplish intravenous, intramuscular or subcutaneous 
administration, and for such parenteral administration, 
suitable sterile aqueous or non-aqueous solutions or 
suspensions, optionally containing appropriate solutes 
to effect isotonicity, will be employed. Likewise for 
inhalation dosage forms, for administration through the 
mucous membranes of the nose and throat or bronchio 
pulmonary tissues, suitable aerosol or spray inhalation 
compositions and devices will be utilized. 
The foregoing methodology allows for the prepara 
tion of microspheres in controlled size ranges under 
conditions sufficiently mild to preserve the biological 
activity of functional macromolecules. In addition, the 
foregoing methodology allows for the potential for 
controlling the release of the drug by controlling the 
crosslinking density and the rate of degradation via 
selecting the derivatization degree of the starting poly 
saccharide and matrix composition. 
The polymerization may be conducted by any poly 
merization process known in the art, however, another 
important feature of the present invention is the fact 
that the polymerization can be conducted using a bead 
polymerization technique. According to the convenient 
process described in the present invention, the deriva 
tized biodegradable hydrophilic polymer, the monovi 
nyl monomer and the biologically active macromole 
cule which is to be incorporated therein are codissolved 
in an aqueous buffer of appropriate pH and ionic 
strength which is suitable for preserving the biological 
activity of the macromolecular agent, usually together 
with one component of the initiator system. Either oxi 
dative or reductive types of initiators are useful. 
The aqueous solution is then deoxygenated by purg 
ing with N2 and emulsi?ed in a deoxygenated water 
immiscible organic liquid, preferentially composed of 
higher aliphatic hydrocarbons such as hexane, heptane, 
octane, cyclohexane, or their higher homolo gs and their 
mixtures. In order to facilitate the emulsiflcation and 
formation of a water-in-oil emulsion, appropriate emul 
sifying agents are added to the continuous organic 
phase. Typical emulsifying agents include sorbitan ole 
ates, polyethylene glycol ethers, polyoxyethylene sorbi 
tan esters, polyoxyethylene polyoxypropylene alcohols, 
and the like. 
After obtaining an emulsion having a suitable size 
range of aqueous droplets, the polymerization is begun 
by addition of the other component of the initiator 
system to the emulsion. When a water soluble com 
pound is used, the oxidant component of the initiator 
system, e.g., ammonium persulfate and the like, is in the 
aqueous dispersed phase, then the second component is 
a reductant soluble in the continuous phase, e.g., 
N,N,N’,’-tetramethylethylenediamine and the like. The 
microspheres formed by the polymerization of the aque 
ous droplets of the emulsion are cleansed by decantation 
and washed with an appropriate water-immiscible or 
ganic solvent and then freeze dried. Suitable organic 
water-immiscible solvents include cyclohexane, ben 
zene, cyclohexanone, and the like. 
Following another procedure according to the pres 
ent invention, the microspheres after washing with 
4,741,872 
organic solvent can be redispersed in water or an aque 
ous buffer, washed with the buffer and freeze-dried 
from an aqueous suspension. The biologically active 
compound, e.g., peptide, protein, and the like, while 
co-dissolved in the aqueous dispersed phase, is en 
trapped in the crosslinked polymer network during 
polymerization and can be released in vivo essentially 
by the diffusion through the polymer network or fol 
lowing the degradation of the matrix. 
A particularly advantageous feature of the foregoing 
process, and irrespective of the particular polymeriza 
tion technique selected, is that the microspheres can be 
prepared in a variety of size ranges generally ranging 
from about 0.5 pm to about 500 pm in diameter. Size 
ranges from about 1.0 pm to about 15.0 pm in diameter 
are generally preferred. For inhalation administration a 
microsphere size range of from about 1.0 pm to about 
5.0 pm in diameter is preferred. For injectable adminis 
tration a microsphere size range of about 8.0 pm to 
about 15.0 pm in diameter is preferred. 
The size of the resulting microspheres depends on the 
size of the aqueous droplets in the water-in-oil emulsion. 
The size of the droplets in turn is dependent upon the 
shear stress which is applied by the stirrer. The stirrer 
opposes the coalescing tendencies caused by surface 
tension. Generally, the size of the droplets is reduced by 
applying a higher shear stress. A higher shear stress is 
achieved either by using a higher stirrer speed or by 
increasing the ratio between the viscosities of the con 
tinuous phase and the dispersed phase. A higher viscos 
ity of the continuous phase may be achieved by increas 
ing the proportion of hydrocarbons with more carbon 
atoms in the emulsion, e.g., octane, dioxane, dodecane 
and the like. The viscosity of the aqueous dispersed 
phase may be adjusted by using a different molecular 
weight of the starting biodegradable hydrophilic poly 
mer. Adjustment of the viscosity of the aqueous dis 
persed phase in this manner allows for use of the same 
total gel matrix and monovinyl monomer concentra 
tion. 
Another advantageous feature of the present inven 
tion is the fact that the incorporated macromolecular 
agents are released from the gel matrix by a diffusion 
through the crosslinked hydrogel network. Various 
rates of release of the macromolecular agents may be 
achieved by varying the crosslinking density of the gel 
matrix. The crosslinking density of the matrix may be 
varied by selecting a biodegradable hydrophilic poly 
mer with varying degrees of derivatization (DD). De 
grees of derivatization are used to indicate the average 
distance between the attached vinylic groups. A suit 
able crosslinking density is also dependent on the mo 
lecular weight of the macromolecular agent and on the 
desired rate of its release. 
The degree of derivatization is preferably in the range 
of about 0.01 to about 0.20 mole of vinyl groups per 
mole of monomer units of the biodegradable hydro 
philic starting polymer. Preferably, there are about 0.02 
to about 0.15 mole of vinyl groups per mole of mono 
mer units of the starting polymer. If hydroxyethyl 
starch (HES) is used as the starting biodegradable hy 
drophilic polymer, the broad range of about 0.01 to 
about 0.20 corresponds to a molecular weight of the 
average segment between crosslinking points of about 
20,000 to about 1000, respectively. About 0.02 to about 
0.15 corresponds to a molecular weight range of the 
average segment between the crosslinking points of 
about 10,000 to about 1,800. The range in cross-linking 
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density of 0.02 to 0.15 moles of vinyl groups per moles 
of monomer units will produce approximately a ten-fold 
difference in the release rate of the protein having a 
molecular weight of about 50,000. 
It will be appreciated that the concentrations, tem 
peratures and ratios referred to hereinabove and in the 
examples set forth operable ranges and that other nu 
merical expressions may apply as different solvents, 
polymers, monomers, macromolecules, etc. are se 
lected. 
The following non-limiting examples are offered in 
order that those skilled in the art may more readily 
understand the present invention and the speci?c pre 
ferred embodiments thereof. Unless indicated other 
wise, all amounts are given in grams. 
EXAMPLE 1 
To a solution of hydroxyethyl starch (HES) (HES 
PAN, a trademark of American Critical Care) in dry, 
distilled N,N’-dimethylacetamide (DMAA) at approxi 
mately 0° C., a measured amount of distilled acryloyl 
chloride was added in small portions along with an 
equimolar amount of triethylamine, over approximately 
a 30 minute time period. The reaction vessel was main 
tained at this temperature and the reaction proceeded 
for approximately 2 additional hours. The reaction mix 
ture was then transferred to a vessel containing 200 ml 
of acetone at about 0° C. to about 5° C. to precipitate the 
polymer. The polymer was washed with acetone, dried 
with air suction, dissolved in water and reprecipitated in 
acetone. Derivatized HES (acryloyl-HES) was finally 
puri?ed by preparative gel permeation chromatography 
in water and then freeze-dried. Ratios of the reactants 
and the data on the resulting polymers are presented in 
Table l. The symbol mwA represents the molecular 
weight equivalent of the biodegradable hydrophilic 
polymer per vinyl group. D.D. represents the degree of 
derivatization in millimole/ gram. 
TABLE I 
Preparation of Acgloyl-HES 
la lb 10 1d 
HES 5.0 5.0 5.0 5.0 
DMAA 18.8 18.8 18.8 18.8 
Acryloyl chloride 0.1 0.2 0.4 1.0 
Triethylamine 0.1 l 0.22 0.45 1.1 
Acryloyl-HES (yield) 4.3 4.3 4.6 5.1 
D.D. (mmole/gram) 0.07 0.17 0.26 0.62 
mwA 14,300 6,000 3,800 1,600 
EXAMPLE 2 
Approximately 4.05 grams of partially hydrolyzed 
amylopectin was dissolved in 80 ml of water. The solu 
tion was cooled to 0° C. and the solution of 1.8 grams of 
acryloyl chloride in 10 ml of acetone was added in small 
portions during stirring along with 10 ml of 2N solution 
of NaOH so that the solution was remained alkaline. 
After approximately 30 minutes the acryloyl-amylopec 
tin was precipitated with acetone and further processed 
in a manner similar to Example 1. The yield was 3.9 
grams and the DD. was 0.32 mmole/ gram. 
EXAMPLE 3 
Approximately 5.0 grams of HES was dissolved in 
18.8 grams of DMAA and to this solution was added 6 
ml of 2N solution of NaOH, 50 mg of 4-methoxyphenol 
and 1.4 grams of allylglycidyl ether. The resulting mix 
ture was stirred for 20 hours at room temperature and 
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then processed in a manner similar to Example 1. The 
yield was 4.3 grams and ‘the DD. was 0.42 mmole/ 
gram. 
EXAMPLE 4 
Approximately 4.3 grams of poIy-[N-(Z-hydroxye 
thyl)-L-glutamine], (PHEG), in 18.8 grams of DMAA 
was reacted with 0.4 grams of acryloyl chloride in a 
procedure similar to that used in Example 1. The yield 
of acryloyl-PHEG was 4.2 grams and the DD. was 0.32 
mmole/gram. 
EXAMPLE 5 
Acryloyl-HES, prepared according to Example 1, 
acrylamide and alpha-l-proteinase inhibitor (alpha-l 
PI) were dissolved in 0.05 mole/liter ammonium car 
bonate buffer pH 7.4, together with ammonium persul 
phate (2% mole/mole in terms of the total concentra 
tion of vinyl groups). The solution was deoxygenated 
by repeated evacuation and ?lling of the vessel with 
nitrogen at 0° C. The deoxygenated solution was ?l 
tered and the ?ltrate was transferred to a polymeriza 
tion reactor containing 60 ml of organic continuous 
phase. The organic continuous phase was composed of 
a mixture of heptane, USP, mineral oil and 0.3 gram of 
50-15 (sorbitan oleate). The entire mixture was then 
?ushed with nitrogen at 0° C. Table II provides a de-: 
scription of the compositions of the dispersed and con 
tinuous phases. In Table II, average diameter (pm) 
represents the average diameter of the microspheres 
after rehydration in 0.15 mole/liter NaCl and 0.05 
mole/liter phosphate pH 7.4. The protein content % 
represents the content of the diffusion releasable protein 
in dry microspheres. 
The polymerization reactor consisted of a jacketed 
glass vess'el equipped with a controlled-speed stirrer. 
Ports for addition of reactants and withdrawal of sam 
ples as well as nitrogen inlet were provided in the ves 
sel-top assembly. When a stable emulsion of the aqueous 
dispersed phase in the organic continuous phase was 
obtained by the action of the stirrer, approximately 0.15 
ml of N,N,N',N'-tetramethylenediamine (TEMED) 
was added to the emulsion and the reaction proceeded 
at about 0° to 2° C. for another 20 minutes. The result 
ing suspension of microspheres was poured in 200 ml of 
cold heptane (0°—5° C.), washed with heptane, resus 
pended in ammonium carbonate buffer containing 0.1% 
of Triton-X400, washed with pure ammonium carbon 
ate buffer (0.01 mole/liter) and freeze-dried. 
TABLE II 
Reaction conditions and characteristics of the product 
a b c d e f g h 
Dispersed 
phase: 
Acryloyl- 1.76 1.76 1.76 2.00 2.00 2.00 2.00 2.00 
HES 
Acrylamide 0.40 0.40 0.40 0.50 0.50 0.50 0.50 0.50 
Alpha-l-Pl 0.34 0.34 2.20 0.60 0.60 0.60 0.60 0.60 
Buffer 17.50 17.50 15.60 16.90 16.90 16.90 16.90 16.90 
mwA 3,800 6,000 3,800 3,800 6,000 6,000 6,000 6,000 
Continuous 
Heptane (ml) 17 17 17 17 17 17 40 10 
Mineral oil 43 43 43 43 43 43 20 50 
(ml) 
Stirring 1,600 1,600 1,600 1,600 800 2,200 2,200 2,200 
(rpm) 
Average 8.6 14.0 12.5 7.6 28.0 5.3 46.0 3.6 
diameter 
(um) 
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TABLE II-continued 
Reaction conditions and characteristics of the product 
a b c d e f g h 
4.7 4.5 22.8 9.4 Protein 
content % 
EXAMPLE 6 
Example 6 was conducted in a manner similar to 
Example 5, except that the product was washed with 
heptane, then washed with cyclohexane and ?nally 
freeze-dried from cyclohexane. The resulting micro 
spheres exhibited properties analogous to those found in 
Example 5 but contained essentially all of the protein 
which had been initially added in the dispersed phase. 
EXAMPLE 7 
Approximately 1.6 grams of acryloyl-PHEG, pre 
pared according to Example 4, 0.58 gram of N-vinyl-2 
pyrrolidone and 0.49 gram of alpha-l-proteinase inhibi 
tor (alpha-l-PI) in 13.5 ml of 0.05 mole/liter phosphate 
buffer pH 7.4 were used as a dispersed phase to prepare 
microspheres in a manner similar to that set forth in 
Example 5d. The resulting microspheres had an average 
diameter of 6.7 pm and a protein content of 11.2%. 
EXAMPLE 8 
Approximately 50 mg of microspheres prepared in a 
manner similar to that used in Examples Sa-d were 
suspended in 10 ml 0.05 mole/liter phosphate buffer pH 
7.4 with 0.15 mole/liter NaCl and 0.02% NaN3. The 
suspensions were placed in capped test tubes and were 
incubated'at 37° C. with continuous agitation. Samples 
of the suspensions were withdrawn at convenient inter 
vals and the microspheres were separated by centrifuga 
tion. The residual amount of the protein in the micro 
spheres, the concentration of protein in microspheres 
and the concentration of protein in the incubation me 
dium were determined using the method of Lowry et al. 
(OH. Lowry et al., J. Biol. Chem, 193: 265, 1951). The 
amount of alpha-l-PI released as function of time is 
presented in FIG. 2. FIG. 3 describes the cumulative 
release of alpha-l-PI from HES-polyacrylamide micro 
spheres in pg of protein per mg of spheres. The incuba 
tion time is plotted in a square root scale. Characteris 
tics of microspheres are those as in Table 2. Characteris 
tics of the microspheres corresponds to those given in 
Example Sa-d. 
While this invention has been described and illus 
trated with reference to certain preferred embodiments 
thereof, those skilled in the art will appreciate that vari 
ous changes, modi?cations and substitutions can be 
made therein without departing from the spirit of the 
invention. It is intended, therefore, that the invention be 
limited only by the scope of the claims which follow. 
What is claimed is: 
1. A method for preparing biodegradable micro 
spheres having a three-dimensional network in which 
biologically active macromolecular agents are physi 
cally entraoped therein, said microsphere being able to 
release the macromolecular agent at a controlled rate, 
comprising emulsifying a vinyl derivative of a biode 
gradable hydrophilic polymer, a water-soluble monovi 
nyl monomer and a biologically active macromolecule 
in water, and copolymerizing the biodegradable hydro 
philic polymer and the water-soluble monovinyl mono 
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mer such that the biologically active macromolecule is 
entrapped therein. 
2. The method according to claim 1, wherein the 
biodegradable hydrophilic polymer is prepared by the 
copolymerization of a vinyl derivative of a biodegrad 
able hydrophilic polymer which contains at least two 
vinyl groups or substituted vinyl groups per average 
polymer chain. 
3. The method according to claim 2, wherein the 
vinyl derivative of the biodegradable hydrophilic poly 
mer has the formula: 
CH2=CRl—(CH2)n—X (I) 
wherein R1 is a hydrogen atom or a methyl group; n is 
O, l or 2; X is a radical having the formula: 
and R2 represents the biodegradable hydrophilic poly 
mer which contains at least two vinyl or substituted 
vinyl groups per average polymer chain. 
4. The method according to claim 3, wherein the 
biodegradable hydrophilic polymer is selected from the 
group consisting of polysaccharides, proteinaceous pol 
ymers, soluble derivatives of polysaccharides, soluble 
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derivatives of proteinaceous polymers, polypeptides, 
polyesters, and polyorthoesters. 
5. The method according to claim 4, wherein the 
biodegradable hydrophilic polymer is a polysaccharide. 
6. The method according to claim 5, wherein the 
polysaccharide is a starch derivative. . 
7. The method according to claim 4, wherein the 
biodegradable hydrophilic polymer is a polypeptide. 
8. The method according to claim 7, wherein the 
polypeptide is poly-(N—hydroxyalkyl)asparagine or 
poly-(N-hydroxyalkyDglutamine. 
9. The method according to claim 1, wherein the 
water-soluble monovinyl monomer is selected from the 
group consisting of hydrophilic esters and/ or amides of 
acrylic or methacrylic acids, water-soluble vinyl deriv 
atives, acrylic acid and methacrylic acid. 
10. The method according to claim 1, wherein the 
ratio between the biodegradable hydrophilic polymer 
to the water-soluble monovinyl monomer is in the range 
of about 1:5 to about 40:1 on a weight basis. 
11. The method according to claim 1, wherein the 
biologically active macromolecular agent is a hormone, 
protein, peptide, vaccine, enzyme or enzyme inhibitor. 
12. The method according to claim 1, wherein the 
polymerization is conducted at a temperature of about 
0° C. to about 50° C. 
13. The method according to claim 1, wherein the 
polymerization is conducted using the bead polymeriza 
tion technique. 
* * * * 1k 
